Evolving IO Management Strategies in Cutaneous Squamous Cell Carcinoma

Eric Whitman, MD, medical director, oncology service line, Atlantic Health System; Vishal Patel, MD, FAAD, FACMS, associate professor, dermatology and medicine, GW School of Medicine & Health Sciences, director, Cutaneous Oncology Program, GW Cancer Center

Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

ByEric Whitman, MD,Vishal A. Patel, MD, FAAD, FACMS

January 31st 2026

Drs Whitman and Patel discuss the evolving treatment paradigm for patients with CSCC, emphasizing the role of neoadjuvant and adjuvant immunotherapies.

Evolving IO Management Strategies in Cutaneous Squamous Cell Carcinoma

Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care